Soutron Global 2024 Milestones: Expanded Product Line, Experienced Double-digit Growth and More
'Strengthened by our 2024 accomplishments, double-digit growth and acquisitions, we are looking forward to continuing to deliver comprehensive and expanded solutions for our clients.' — Tony Saadat, President & CEO of Soutron Global
SAN DIEGO, CA, UNITED STATES, February 4, 2025 / EINPresswire.com / -- Soutron Global, an internationally recognized SaaS provider of information management and preservation solutions for archives, libraries, museums and knowledge management hubs announces its accomplishment of a series of milestones in 2024.
From strategic acquisitions to software development, the company continued to demonstrate its commitment to empowering organizations with comprehensive solutions for managing knowledge, information, and diverse special collections.
Key achievements include:
Expanding the Team and Product Line
In December 2024, Soutron Global acquired MINISIS Inc., a Vancouver-based provider of archive, library, museum and preservation management solutions. This milestone expanded Soutron's portfolio, strengthening its ability to serve a broader range of industries worldwide.
Double-digit Growth
The Soutron client base continued its growth, with the addition of key clients spanning engineering, financial, construction, maritime, special academic and government agencies around the globe.
Expanded Commitment to Data Privacy and Security
Soutron Global demonstrated its commitment to GDPR and the Data Privacy Framework (DPF) by renewing its self-certification in October 2024, reinforcing its dedication to protecting client data and maintaining high standards of privacy and security.
Expansion of Global Partnerships
In January 2024, Soutron Global expanded its Partner Program to include resellers and new international regions, broadening its global presence and fostering new collaborative opportunities.
Software Innovation and Enhancements
The release of Soutron Software Version 4.1.11 introduced a redesigned administrative system configuration view, improved copy management workflows, along with an enhanced hierarchical tree catalogue view. This release was designed to improve user experiences, increase system flexibility, and streamline information management for special libraries and archives, demonstrating Soutron's continued investment in innovation, usability and client satisfaction.
Industry Profile Articles Published
Published articles for Companies such as Rochester Electronics, National Association of Realtors (NAR), and LaFrance Corporation, outlined how our information management solutions replaced document management, learning management, and open-source library and archive solutions to provide advanced information management solutions.
Client User Group, Roundtable and Focus Group Meetings
Several client user group, roundtable and focus group meetings were held in 2024, where modernized administrative workflows and new search features were reviewed, in addition to exploring how best to implement AI into Soutron solutions.
Podcasts & eBooks
Released podcasts discussed metadata, taxonomies, learning management and knowledge management in project teams, and covered the knowledge transfer gap in HR information management. Also published was an Information Management eBook containing a review of modern information management best practices.
Exhibitions and Conferences
Participated in various conferences, including KMWorld, the Society of American Archivists Annual Meeting, the CALL/ACBD Legal Canadian conference and AALL Law Library Conference.
Message from Tony Saadat, Soutron President & CEO
'2024 has been a year of transformative growth for Soutron Global, demonstrating our ability to unlock potential and drive meaningful information management practices across the industries we serve,' states Tony Saadat, President & CEO of Soutron Global. 'Strengthened by our 2024 accomplishments, double-digit growth and acquisitions, we are looking forward to continuing to deliver comprehensive and expanded solutions for our clients.'
About Soutron Global, Inc.
Soutron Global is an internationally recognized SaaS provider of transformative information management and preservation solutions for archives, libraries, museums and knowledge management hubs. Backed by decades of experience, award-winning leadership and a commitment to innovation, we empower organizations of all types to transform how they organize, access, preserve and deliver their collection assets. From library holdings and proprietary knowledge to cultural artifacts and archival assets, Soutron Global solutions enhance access, preservation, and findability. Dedicated to exceeding client expectations, we embrace new challenges and consider our clients' success to be our success.
Tony Saadat
X
LinkedIn
YouTube
Legal Disclaimer:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Evri to hire thousands more couriers after deal with DHL
Evri is set to expand its courier network with a recruitment drive for 5,000 new couriers, as the company looks to compete in the business letter market. The Yorkshire-based parcel firm recently announced a collaboration with DHL's UK ecommerce division, creating one of the UK's largest delivery networks. The addition of these new roles will bring Evri's total number of self-employed couriers to 33,000. These positions will be available across the UK, with a focus on areas such as Plymouth, Bury, Hastings, Dover, and Scarborough. Approximately 1,000 of the new jobs will be permanent, while the remainder will be flexible roles designed to accommodate the increased demand during the summer and other peak delivery periods. Couriers who commit to working five or more days a week, including Saturday and Sunday, are also given the chance to opt in to its revamped 'Evri Plus' scheme, which includes paid holiday and automatic enrolment into a pension scheme. Evri, which was previously part of the Hermes parcel group, was bought by US private equity firm Apollo for around £2.7 billion last year. It announced plans last month to merge with rival DHL's UK ecommerce business to create a combined company set to deliver more than one billion parcels and one billion letters each year. The deal means Evri will enter the UK business letter market for the first time, bolstering its competition to Royal Mail. Evri has spent £32 million on improving its customer service offering and has seen an improvement in its ratings over recent years, but has said there is 'more to do' to improve with customers continuing to report delivery issues. Chief executive Martijn de Lange said: 'We know that service, reliability and quality are critical factors for our clients and consumers, and so by expanding our self-employed network further, we remain focused on delivering in each of those areas.' Couriers typically earn about £20.90 an hour on average, according to Evri. Sign in to access your portfolio
